Establishment Labs Holdings Inc. ESTA
We take great care to ensure that the data presented and summarized in this overview for ESTABLISHMENT LABS HOLDINGS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ESTA
View all-
Jw Asset Management, LLC Armonk, NY3.09MShares$113 Million73.4% of portfolio
-
Rtw Investments, LP New York, NY2.58MShares$94.6 Million1.73% of portfolio
-
Brown Advisory Inc2.29MShares$84 Million0.14% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.95MShares$71.2 Million0.02% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.77MShares$65 Million3.26% of portfolio
-
Findell Capital Management LLC New York, NY1.38MShares$50.7 Million27.65% of portfolio
-
Tyro Capital Management LLC New York, NY1.06MShares$39 Million16.18% of portfolio
-
William Blair Investment Management, LLC Chicago, IL847KShares$31 Million0.11% of portfolio
-
Rice Hall James & Associates, LLC827KShares$30.3 Million2.21% of portfolio
-
Bamco Inc New York, NY747KShares$27.3 Million0.09% of portfolio
Latest Institutional Activity in ESTA
Top Purchases
Top Sells
About ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Insider Transactions at ESTA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 23
2025
|
Quiros Juan Jose Chacon Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+1.57%
|
-
|
|
May 23
2025
|
Ann Custin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+14.53%
|
-
|
|
May 23
2025
|
Leslie Gillin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+18.83%
|
-
|
|
May 23
2025
|
Bryan Slotkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+10.54%
|
-
|
|
May 23
2025
|
Nicholas Sheridan Lewin Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+0.32%
|
-
|
|
May 23
2025
|
Edward J Schutter Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,413
+1.08%
|
-
|
|
May 14
2025
|
Filippo Caldini Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,856
+17.47%
|
-
|
|
Mar 31
2025
|
Bryan Slotkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
398
+1.53%
|
$15,920
$40.81 P/Share
|
|
Mar 31
2025
|
Nicholas Sheridan Lewin Director |
BUY
Grant, award, or other acquisition
|
Direct |
612
+0.06%
|
$24,480
$40.81 P/Share
|
|
Mar 31
2025
|
Edward J Schutter Director |
BUY
Grant, award, or other acquisition
|
Direct |
459
+0.15%
|
$18,360
$40.81 P/Share
|
|
Mar 31
2025
|
Ann Custin Director |
BUY
Grant, award, or other acquisition
|
Direct |
474
+2.77%
|
$18,960
$40.81 P/Share
|
|
Mar 31
2025
|
Leslie Gillin Director |
BUY
Grant, award, or other acquisition
|
Direct |
413
+3.53%
|
$16,520
$40.81 P/Share
|
|
Mar 13
2025
|
Raj Denhoy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,200
+32.42%
|
-
|
|
Mar 13
2025
|
Samuel Ross Mansbach |
BUY
Grant, award, or other acquisition
|
Direct |
7,952
+34.29%
|
-
|
|
Mar 13
2025
|
Filippo Caldini Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,231
+40.29%
|
-
|
|
Mar 13
2025
|
Filippo Caldini Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
770
-8.48%
|
$26,180
$34.82 P/Share
|
|
Mar 06
2025
|
Raj Denhoy Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
985
-7.5%
|
$41,370
$42.08 P/Share
|
|
Mar 06
2025
|
Samuel Ross Mansbach |
SELL
Payment of exercise price or tax liability
|
Direct |
728
-9.08%
|
$30,576
$42.08 P/Share
|
|
Dec 31
2024
|
Ann Custin Director |
BUY
Grant, award, or other acquisition
|
Direct |
420
+2.53%
|
$19,320
$46.07 P/Share
|
|
Dec 31
2024
|
Bryan Slotkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
352
+1.38%
|
$16,192
$46.07 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 82.5K shares |
|---|
| Payment of exercise price or tax liability | 2.48K shares |
|---|---|
| Open market or private sale | 115K shares |